Source 1primary paper2025MED
Toolkit/GPRTG stable producer cell line
GPRTG stable producer cell line
Also known as: GPRTG producer cell line, GPRTG stable producer cell line
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The GPRTG producer cell line showed 6-fold higher LV titer and resulted in better transduction of CD34+ cells.
Usefulness & Problems
Why this is useful
This is a stable producer cell line used to generate lentiviral vector for Wiskott-Aldrich syndrome-related applications. In the abstract it is the better-performing producer background among the compared lines.; stable lentiviral vector production for WAS-related ex vivo gene therapy manufacturing; higher-titer LV production than the compared GPRG-derived producer line
Source:
This is a stable producer cell line used to generate lentiviral vector for Wiskott-Aldrich syndrome-related applications. In the abstract it is the better-performing producer background among the compared lines.
Source:
stable lentiviral vector production for WAS-related ex vivo gene therapy manufacturing
Source:
higher-titer LV production than the compared GPRG-derived producer line
Problem solved
It addresses the need for scalable, high-quality LV production with strong transduction performance. The abstract specifically links it to higher titer and better CD34+ transduction than the compared alternative.; improves lentiviral titer in a stable producer-cell-line setting; supports downstream CD34+ cell transduction with produced LV
Source:
It addresses the need for scalable, high-quality LV production with strong transduction performance. The abstract specifically links it to higher titer and better CD34+ transduction than the compared alternative.
Source:
improves lentiviral titer in a stable producer-cell-line setting
Source:
supports downstream CD34+ cell transduction with produced LV
Problem links
improves lentiviral titer in a stable producer-cell-line setting
LiteratureIt addresses the need for scalable, high-quality LV production with strong transduction performance. The abstract specifically links it to higher titer and better CD34+ transduction than the compared alternative.
Source:
It addresses the need for scalable, high-quality LV production with strong transduction performance. The abstract specifically links it to higher titer and better CD34+ transduction than the compared alternative.
supports downstream CD34+ cell transduction with produced LV
LiteratureIt addresses the need for scalable, high-quality LV production with strong transduction performance. The abstract specifically links it to higher titer and better CD34+ transduction than the compared alternative.
Source:
It addresses the need for scalable, high-quality LV production with strong transduction performance. The abstract specifically links it to higher titer and better CD34+ transduction than the compared alternative.
Published Workflows
Objective: Establish a scalable, high-quality lentiviral manufacturing platform for Wiskott-Aldrich syndrome ex vivo gene therapy by combining stable producer-cell-line selection with process optimization and scale-up in adherent bioreactors.
Why it works: The abstract frames the approach as synergistically combining efficient vector design with LV process optimization, then narrowing to the better producer cell line and better-performing bioreactor platform before scale-up and functional transduction testing.
stable producer cell line-based lentiviral generationcontinuous perfusion and recirculation manufacturingtransfection reagent evaluationproducer cell line comparisonbioreactor platform comparisonscale-up from 2.4 m2 to 10 m2
Stages
- 1.Producer cell line generation and comparison(library_build)
This stage identifies the better stable producer-cell-line background before committing to process optimization and scale-up.
Selection: Generate stable producer cell lines from GPRG and GPRTG packaging cell lines and compare resulting LV titer and CD34+ transduction performance.
- 2.Manufacturing technology comparison in continuous perfusion mode(broad_screen)
This stage identifies the better production hardware platform after selecting the producer cell line.
Selection: Compare traditional flatware systems, iCELLis Nano, and scale-X Hydro using the GPRTG stable producer cell line in continuous perfusion and recirculation mode.
- 3.Scale-up production in scale-X Carbo(confirmatory_validation)
This stage confirms that the selected process can be transferred to a larger manufacturing scale.
Selection: Scale the selected process from scale-X Hydro to scale-X Carbo and measure total TU output across harvests.
- 4.Functional transduction validation in CD34+ cells(confirmatory_validation)
This stage checks that process optimization and scale-up preserve the intended functional output of the LV product.
Selection: Test whether LV produced by the optimized continuous perfusion process efficiently transduces CD34+ cells and achieves measurable VCN at defined MOI.
Steps
- 1.Evaluate transfection reagents to generate stable producer cell lines from GPRG and GPRTG packaging cell linesproducer cell line candidates
Create stable producer cell lines expressing WAS or GFP transgenes from two Tet-off regulated packaging-cell-line backgrounds.
Producer cell lines had to be generated before their LV output and downstream manufacturing suitability could be compared.
- 2.Compare producer cell lines by LV titer and CD34+ transduction performancecompared producer cell line platforms
Identify the better producer cell line for downstream process optimization.
The study needed to choose the stronger producer background before investing in bioreactor process comparison and scale-up.
- 3.Optimize continuous perfusion and recirculation LV production using the selected GPRTG producer cell line across flatware, iCELLis Nano, and scale-X Hydroselected producer line and compared manufacturing platforms
Determine which production technology gives better LV productivity per surface area under the optimized process mode.
After selecting the better producer cell line, the next decision was which manufacturing platform best supports scalable production.
- 4.Scale the selected process from scale-X Hydro to scale-X Carbo and collect multiple harvestsscale-up manufacturing platforms
Demonstrate that the selected continuous perfusion process can be transferred to a larger 10 m2 platform while maintaining high output.
Scale-up follows platform selection because only the preferred process configuration is worth testing at larger manufacturing scale.
- 5.Test LV from the optimized process for CD34+ cell transduction and VCN at MOI 10
Confirm that the optimized and scaled manufacturing process still yields functionally active LV for the intended ex vivo application.
Functional testing is done after process optimization and scale-up to ensure manufacturing improvements did not compromise biological performance.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
No mechanism tags yet.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: actuator
The reported use requires Tet-off regulated adherent stable LV packaging-cell-line infrastructure and downstream LV production hardware such as flatware or adherent bioreactors. The abstract also places it in a continuous perfusion and recirculation process.; requires Tet-off regulated adherent stable LV packaging-cell-line context; requires continuous perfusion manufacturing process for the reported scale-up results
The abstract does not show that this cell line alone solves all manufacturing or product-quality questions. It also does not provide detailed release, safety, or long-term stability data.; abstract does not specify exact transfection reagent, clone architecture, or full build details
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
scale-X Hydro had higher lentiviral productivity per surface area than iCELLis Nano in the reported process comparison.
The GPRTG producer cell line produced higher lentiviral titer than the compared GPRG-derived producer cell line and gave better CD34+ cell transduction.
LV titer fold change 6 fold
The study established a scalable, cost-effective, and robust platform for lentiviral production with potential clinical application.
Lentiviral production was successfully scaled from scale-X Hydro to scale-X Carbo using the continuous perfusion process.
number of harvests 7 harveststotal lentiviral output 1130000000000 TU per 10 m2
Approval Evidence
1 source2 linked approval claimsfirst-pass slug gprtg-stable-producer-cell-line
The GPRTG producer cell line showed 6-fold higher LV titer and resulted in better transduction of CD34+ cells.
Source:
comparative performancesupports
The GPRTG producer cell line produced higher lentiviral titer than the compared GPRG-derived producer cell line and gave better CD34+ cell transduction.
Source:
platform characterizationsupports
The study established a scalable, cost-effective, and robust platform for lentiviral production with potential clinical application.
Source:
Comparisons
Source-stated alternatives
The paper contrasts GPRTG with GPRG as an alternative producer-cell-line background. It also compares manufacturing hardware including traditional flatware, iCELLis Nano, and scale-X Hydro.
Source:
The paper contrasts GPRTG with GPRG as an alternative producer-cell-line background. It also compares manufacturing hardware including traditional flatware, iCELLis Nano, and scale-X Hydro.
Source-backed strengths
showed 6-fold higher LV titer than the compared producer cell line; resulted in better transduction of CD34+ cells; was used across flatware and adherent bioreactor process optimization and scale-up
Source:
showed 6-fold higher LV titer than the compared producer cell line
Source:
resulted in better transduction of CD34+ cells
Source:
was used across flatware and adherent bioreactor process optimization and scale-up
Ranked Citations
- 1.